Trine Naalsund Andreassen

Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study

Trine Naalsund Andreassen, Ingrid Eftedal, Pål Klepstad et al. · European Journal of Clinical Pharmacology · 2011 · 115 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients

Trine Naalsund Andreassen, Pål Klepstad, Andrew Davies et al. · European Journal of Clinical Pharmacology · 2010 · 60 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Quantifying Alcohol Consumption in the General Population by Analysing Phosphatidylethanol Concentrations in Whole Blood: Results from 24,574 Subjects Included in the HUNT4 Study

Ragnhild Bergene Skråstad, Trond Oskar Aamo, Trine Naalsund Andreassen et al. · Alcohol and Alcoholism · 2023 · 45 citations · Full text

Pharmacy, Toxicology, Alcohol Toxicology +13

High Throughput UPLC®-MSMS Method for the Analysis of Phosphatidylethanol (PEth) 16:0/18:1, a Specific Biomarker for Alcohol Consumption, in Whole Blood

Trine Naalsund Andreassen, Hilde Havnen, Olav Spigset et al. · Journal of Analytical Toxicology · 2017 · 37 citations

Pharmacy, Biochemistry, Toxicology +17

Stability of Phosphatidylethanol 16:0/18:1 in Freshly Drawn, Authentic Samples from Healthy Volunteers

Ragnhild Bergene Skråstad, Olav Spigset, Trond Oskar Aamo et al. · Journal of Analytical Toxicology · 2020 · 34 citations · Full text

Pharmacy, Biochemistry, Toxicology +12